Drug Trial Radar · NCT03258931
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
214
Actual
Start
Aug 15, 2018
Primary completion
Apr 6, 2026
Study completion Apr 6, 2026
Sponsor
- Lead sponsor
- Arog Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 23, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3 mutation. About 510 subjects will be randomized in a 1:1 ratio to receive either crenolanib in addition to standard first line treatment of AML (chemotherapy and if eligible, transplantation) (arm A) or midostaurin and standard treatment (arm B). Potentially eligible subjects will be registered and tested for the presence of FLT3 mutation. Once the FLT3 mutation status is confirmed and additional eligibility is established, subject will be randomized and enter into the treatment phase.
Conditions
- Newly Diagnosed FLT3 Mutated AML
Interventions
CrenolanibDrug
Crenolanib will be administered orally
MidostaurinDrug
Midostaurin will be administered orally
CytarabineDrug
100 mg/m² IV continuous infusion over 24 hours
DuanorubicinDrug
90 mg/m2 IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survival (EFS)Time frame: 5 years
Locations
31 sites in 1 country. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
Ronald Reagan UCLA Medical Center
Los Angeles, California
US Davis Health
Sacramento, California
Yale Cancer Center
New Haven, Connecticut
Moffitt Cancer Center
Tampa, Florida
Rush Medical Center
Chicago, Illinois
University of Illinois at Chicago
Chicago, Illinois
University of Chicago
Chicago, Illinois
Indiana University
Indianapolis, Indiana
University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Kansas
Kansas City, Kansas
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deacnss Medical Center Oncology
Boston, Massachusetts
Dana-Farber Cancer Insitute
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Henry Ford Health System
Detroit, Michigan
University of Minnesota
Minneapolis, Minnesota
John Theurer Cancer Center at Hackensack UMC
Hackensack, New Jersey
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Roswell Park
Buffalo, New York
New York University
New York, New York
Mount Sinai
New York, New York
Columbia University
New York, New York
Cornell University
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
University of Rochester Medical Center
New York, New York
Montefiore Medical Center
The Bronx, New York
The UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Wake Forest Baptist Health, Section on Hematology & Oncology
Winston-Salem, North Carolina
Oregon Health and Science University
Portland, Oregon
University of Virginia Health System
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.